The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Tanja Stocks

Tanja Stocks

Project manager

Tanja Stocks

Circulating insulin-like growth factor I in relation to melanoma risk in the European prospective investigation into cancer and nutrition


  • Kathryn E. Bradbury
  • Paul N. Appleby
  • Sarah J. Tipper
  • Ruth C. Travis
  • Naomi E. Allen
  • Marina Kvaskoff
  • Kim Overvad
  • Anne Tjønneland
  • Jytte Halkjær
  • Iris Cervenka
  • Yahya Mahamat-Saleh
  • Fabrice Bonnet
  • Rudolf Kaaks
  • Renée T. Fortner
  • Heiner Boeing
  • Antonia Trichopoulou
  • Carlo La Vecchia
  • Alexander J. Stratigos
  • Domenico Palli
  • Sara Grioni
  • Giuseppe Matullo
  • Salvatore Panico
  • Rosario Tumino
  • Petra H. Peeters
  • H. Bas Bueno-de-Mesquita
  • Reza Ghiasvand
  • Marit B. Veierød
  • Elisabete Weiderpass
  • Catalina Bonet
  • Elena Molina
  • José M. Huerta
  • Nerea Larrañaga
  • Aurelio Barricarte
  • Susana Merino
  • Karolin Isaksson
  • Tanja Stocks
  • Ingrid Ljuslinder
  • Oskar Hemmingsson
  • Nick Wareham
  • Kay Tee Khaw
  • Marc J. Gunter
  • Sabina Rinaldi
  • Konstantinos K. Tsilidis
  • Dagfinn Aune
  • Elio Riboli
  • Timothy J. Key

Summary, in English

Insulin-like growth factor-I (IGF-I) regulates cell proliferation and apoptosis, and is thought to play a role in tumour development. Previous prospective studies have shown that higher circulating concentrations of IGF-I are associated with a higher risk of cancers at specific sites, including breast and prostate. No prospective study has examined the association between circulating IGF-I concentrations and melanoma risk. A nested case–control study of 1,221 melanoma cases and 1,221 controls was performed in the European Prospective Investigation into Cancer and Nutrition cohort, a prospective cohort of 520,000 participants recruited from 10 European countries. Conditional logistic regression was used to estimate odds ratios (ORs) for incident melanoma in relation to circulating IGF-I concentrations, measured by immunoassay. Analyses were conditioned on the matching factors and further adjusted for age at blood collection, education, height, BMI, smoking status, alcohol intake, marital status, physical activity and in women only, use of menopausal hormone therapy. There was no significant association between circulating IGF-I concentration and melanoma risk (OR for highest vs lowest fifth = 0.93 [95% confidence interval [CI]: 0.71 to 1.22]). There was no significant heterogeneity in the association between IGF-I concentrations and melanoma risk when subdivided by gender, age at blood collection, BMI, height, age at diagnosis, time between blood collection and diagnosis, or by anatomical site or histological subtype of the tumour (Pheterogeneity≥0.078). We found no evidence for an association between circulating concentrations of IGF-I measured in adulthood and the risk of melanoma.


  • Surgery (Lund)
  • Lund Melanoma Study Group
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • EpiHealth: Epidemiology for Health
  • Diabetes - Cardiovascular Disease

Publishing year







International Journal of Cancer





Document type

Journal article


John Wiley & Sons Inc.


  • Cancer and Oncology


  • biomarker
  • EPIC
  • height
  • insulin-like growth factor I
  • melanoma
  • prospective studies



Research group

  • Lund Melanoma Study Group
  • Diabetes - Cardiovascular Disease


  • ISSN: 0020-7136